Table 5.
Effects of 6 months of chromium or combined chromium with vitamins C and E supplementation on markers of oxidative stress
| Placebo (n = 10) | Cr (n = 10) | Cr + C + E (n = 10) | |
|---|---|---|---|
| TBARS (µmol/L) | |||
| Baseline | 5.43 ± 0.16 | 5.42 ± 0.11 | 5.52 ± 0.11 |
| 6 months | 5.58 ± 0.09 | 4.41 ± 0.10* ** | 3.60 ± 0.07* ** |
| TAS (mmol/L) | |||
| Baseline | 1.10 ± 0.04 | 1.14 ± 0.06 | 1.11 ± 0.05 |
| 6 months | 1.11 ± 0.08 | 1.27 ± 0.04* | 1.31 ± 0.07* |
| SOD (U/g of erythrocytes) | |||
| Baseline | 889.3 ± 31.2 | 895.4 ± 22.7 | 882.8 ± 24.3 |
| 6 months | 894.5 ± 28.7 | 904.0 ± 21.2 | 911.4 ± 29.9 |
| GPx (U/g of erythrocytes) | |||
| Baseline | 9.57 ± 0.82 | 9.63 ± 0.56 | 9.52 ± 0.61 |
| 6 months | 9.54 ± 0.45 | 11.25 ± 0.49* | 11.85 ± 0.62* |
| Catalase (KU/g of erythrocytes) | |||
| Baseline | 12.3 ± 0.8 | 12.1 ± 0.5 | 12.8 ± 0.2 |
| 6 months | 12.4 ± 1.0 | 12.7 ± 1.0 | 12.4 ± 0.4 |
1. Values are the mean ± SD.
2. “*” means significant difference between the placebo group and the Cr or Cr + C + E group.
3. “**” means significant difference between the Cr group and the Cr + C + E group.